Long-term oral antiarrhythmic therapy with mexiletine.
AUTOR(ES)
Campbell, N P
RESUMO
Forty-eight patients with ischaemic heart disease received oral mexiletine for the control or prevention of ventricular arrhythmias. The most frequently used doses were 200, 250, and 300 mg 8-hourly. The treatment period varied from 2 days to more than 1 year (median 3 months). No ventricular arrhythmias were detected in more than one-half of the patients. Severe side effects occurred in 15 (31%) of the 48 patients. Major ventricular arrhythmias were observed in 14 (29%) of the 48 patients at a time when the majority had plasma concentrations within the therapeutic range. The value of mexiletine in the management of patients at risk of sudden death is likely to be limited.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=483486Documentos Relacionados
- Long-Term Oxygen Therapy
- Long-Term Intramuscular Prednisolone Therapy
- Long-term consequences of osteoporosis therapy with denosumab
- The efficacy of long-term oral anticoagulant therapy and its laboratory assessment.
- Blood gold concentrations in children with juvenile rheumatoid arthritis undergoing long-term oral gold therapy.